These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25023055)

  • 1. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors.
    Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
    Med Oncol; 2014 Aug; 31(8):119. PubMed ID: 25023055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
    Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
    Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
    Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
    Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
    Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
    J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
    Yeo W; Chan PK; Zhong S; Ho WM; Steinberg JL; Tam JS; Hui P; Leung NW; Zee B; Johnson PJ
    J Med Virol; 2000 Nov; 62(3):299-307. PubMed ID: 11055239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
    Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
    Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
    Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
    Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
    PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.
    Dai MS; Wu PF; Lu JJ; Shyu RY; Chao TY
    Support Care Cancer; 2004 Mar; 12(3):191-6. PubMed ID: 15074316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.
    Wang YH; Fan L; Wang L; Zhang R; Xu J; Fang C; Li JY; Xu W
    Support Care Cancer; 2013 May; 21(5):1265-71. PubMed ID: 23151650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine.
    Tsai SH; Dai MS; Yu JC; Ho CL; Chen YC; Wu YY; Chang PY; Kao WY; Chao TY
    Support Care Cancer; 2011 Nov; 19(11):1779-87. PubMed ID: 20927554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
    Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
    Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
    Zhang HY; Liu ZG; Zhang Z; Gong HY
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):459-62. PubMed ID: 20819491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.